Distribute Your News Directly to
Readers and Internet Search.
Per Submission
$34.95
— Our Clients —
— Interested Media —
Research submarine dives to the Antarctic seafloor, carried out during a Greenpeace expedition to the Antarctic in January, have identified four separate Vulnerable Marine Ecosystems (VMEs) which have been approved by a group of international Antarctic scientists for special local protection.
Cisco® Application Centric Infrastructure (Cisco ACI™ ) will serve as the foundation for Experian’s data centers and colocation sites around the globe.
Tires specialist Continental is reminding drivers that, even in summer, it is important to allow for longer braking distances when driving on wet roads – particularly after a long spell of dry weather.
Nippon Steel & Sumitomo Metal Corporation (hereinafter “NSSMC”) established “NIPPON STEEL & SUMIKIN COLD HEADING WIRE INDIANA INC. (hereinafter “NSCI”)”, an U.S.
POSCO’s Steel Village project was tabbed by UN as an exceptional illustration of social contribution activity that shifts the paradigm of corporate social responsibility in the global landscape.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today, that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Elecsys® ß-Amyloid (1-42) CSF and Elecsys® Phospho-Tau (181P) CSF.
Renault, European leader in electric vehicles is joining forces with ADA, a subsidiary of the Rousselet Group and leader in local vehicle rental with over 100 agencies in the Paris region.
The Dow Chemical Company (“Dow”) today unveiled its Blueprint for Sustainable Watershed Management to a multi-stakeholder session of The CEO Water Mandate.
Key Points • Researchers successfully used electricity obtained from high-efficiency concentrator photovoltaic cells (with an output of 470 W), currently under research and development at the University of Miyazaki, to electrolyze water, converting 18.8% of the solar energy (daily average) to hydrogen energy.
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved SYMTUZATM, the first and only complete, darunavir-based single-tablet regimen (STR) for the treatment of human immunodeficiency virus type 1 (HIV-1) in treatment-naïve and certain virologically suppressed adults.
